✦ LIBER ✦

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

✍ Scribed by Heather D. Brooks; Bonnie S. Glisson; B. Nebiyou Bekele; Lawrence E. Ginsberg; Adel El-Naggar; Kirk S. Culotta; Naoko Takebe; John Wright; Hai T. Tran; Vassiliki A. Papadimitrakopoulou

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 199 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25769

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of the neck in patients with s

Treatment of the neck in patients with squamous cell carcinoma of the head and neck

✍ Richard H. Jesse; Gilbert H. Fletcher 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB 👁 2 views

Efficacy of neck treatment in patients w

Efficacy of neck treatment in patients with head and neck squamous cell carcinoma

✍ Gabriela Buck; Pia Huguenin; Sandro J. Stoeckli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the

A phase II study of adriamycin in previo

A phase II study of adriamycin in previously untreated squamous cell carcinoma of the head and neck

✍ Melody A. Cobleigh; James H. Hill; Patricia A. Gallagher; Lawrence J. Kukla; Tho 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB 👁 2 views

Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m\* at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 eval

Targeted therapies in squamous cell carc

Targeted therapies in squamous cell carcinoma of the head and neck

✍ Kathryn A. Gold; Ho-Young Lee; Edward S. Kim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 3 views

## Abstract Head and neck cancer is a challenging disease that is expected to account for greater than 500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy and radiation for head and neck cancer, and the prognosis for patients with recurrent and/or metastatic disease r

FDG PET studies during treatment: Predic

FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma

✍ Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract ## Background Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2‐[^18^ F] fluoro‐2‐deoxy‐D‐glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional contr

Sequential methotrexate–5-fluorouracil t

Sequential methotrexate–5-fluorouracil treatment of squamous cell carcinoma of the head and neck

✍ Ulrik Ringborg; GÖSta Ewert; Jan Kinnman; Per-Gotthard Lundqvist; Hans Strander 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 2 views

Thirty-six patients with squamous cell carcinoma of the head and neck were treated with sequential methotrexate-5-fluorouracil followed by leucovorin rescue. The frequency of objective tumor regression obtained was 64% (complete response + partial response) with 19% complete regression. In 20 not pr